Evidence map›Paper›PMID 30567901›Full record

ArticlemSphere2018

Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against

Sanaz Salehi, Claudia M Hohn, Thomas A Penfound, James B Dale

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sanaz Salehi *Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Claudia M Hohn *Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Thomas A PenfoundDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
James B DaleDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA jbdale@uthsc.edu.
University of Tennessee Health Science Center · US

Funding

Structure-Based Design of a Broadly Protective Group A Streptococcal VaccineR01AI132117 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 2017 to 2021
$3.9M
Vaccine Prevention of Group A Streptococcal InfectionsR01AI010085 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DALE, JAMES B. · 1985 to 2016
$2.4M
NIAID NIH HHS R01 AI010085NIAID NIH HHS R01 AI132117
6 · The paper itself

Abstract

The clinical development of group A streptococcal (GAS) vaccines will require the implementation of a standardized, high-throughput assay to measure the activity of functional opsonic antibodies in vaccine recipients. In the present study, we adapted and modified the HL-60-based protocol that was developed for the detection of opsonic antibodies against

Indexed as

PhagocytosisAntibodies, BacterialHL-60 CellsHumansImmunoassayMicrobial ViabilityOpsonin ProteinsSensitivity and SpecificityStreptococcus pyogenesAntibodies, BacterialOpsonin Proteinsgroup A streptococcusopsonic antibodiesStreptococcus pyogenesvaccines

Identifiers

PMID30567901
PMCPMC6300688
OpenAlexW2905904433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.